Dabigatran/P-glycoprotein Inducers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may decrease how much dabigatran is absorbed into your blood.
What might happen:
Your dabigatran may not work as well and your risk of an unwanted blood clot may increase.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor and pharmacist) know that you are taking these medicines together, if you have taken carbamazepine, phenytoin, rifampin, or St. John's wort in the previous week, or if you stop taking carbamazepine, phenytoin, rifampin, or St. John's wort. Your doctor to another may want to change a different medication to prevent blood clots, or adjust the dose of your dabigatran.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. December, 2012.
2.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited August 18, 2011.
3.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim June 13, 2011.
4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
